---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-412300"
form_type: "8-K"
ticker: "BIOA"
cik: "0001709941"
company_name: "BioAge Labs, Inc."
filed_at: "2026-10-02T20:15:14+00:00"
generated_at: "2026-10-12T14:36:32.891215+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# BioAge Labs doses first patient in Phase 2 QUELL-DME trial of oral BGE-102 for DME

## Summary
- First participant dosed in QUELL-DME, a randomized, controlled Phase 2 trial of once-daily oral BGE-102, an NLRP3 inhibitor, in adults with diabetic macular edema.
- Approximately 180 participants randomized 1:1:1: anti-VEGF plus oral placebo; anti-VEGF plus BGE-102 90 mg daily; sham intravitreal injection plus BGE-102 90 mg daily.
- 12 weeks of once-daily dosing with a four-week follow-up; primary endpoint is change in best-corrected visual acuity at week 12, with retinal and biomarker exploratory endpoints.
- Topline results expected in the second half of 2027, and are expected to inform development strategy in other NLRP3-driven retinal diseases including geographic atrophy.

## SEC filing metadata
- accession: 0001193125-26-412300
- form_type: 8-K
- ticker: BIOA
- cik: 0001709941
- company_name: BioAge Labs, Inc.
- filed_at: 2026-10-02T20:15:14+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/0001193125-26-412300-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1709941/000119312526412300/bioa-20261002.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-412300
- JSON: https://secwatch.observer/filing/0001193125-26-412300.json
- Plain text: https://secwatch.observer/filing/0001193125-26-412300.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.